Archives

by in
Entry Author Date Location
East Coast Biotech Roundup: Agios, Vertex, Epizyme, Celldex, & More 11/21/14 Boston
East Coast Biotech Roundup: NJ Blues, Genzyme, Amicus, Biogen & More 08/25/14 Boston
With Persistence And Phase 3 Win, Amicus Nears First Drug Approval 08/20/14 New York
East Coast Biotech Roundup: Amicus, Accelerator, Seventh Sense, & More 08/15/14 Boston
Standing on a Ledge Once Again, Amicus Holds Breath for Latest Study 08/11/14 New York
East Coast Biotech Roundup: Concert, Merrimack, Vertex, & More 05/02/14 Boston
East Coast Biotech Roundup: Moderna, Aileron, Seres, & More 11/22/13 Boston
Amicus Wheels, Deals, Restructures Following Fabry Drug Setback 11/20/13 New York
Amicus, Biogen Team Up on Parkinson’s Drug Deal 09/10/13 Boston
East Coast Life Sciences Roundup: IPO Madness, Amicus, & More 06/21/13 Boston
Amicus Shelves New-Drug Filing For Fabry Disease Drug 06/17/13 New York
East Coast Life Sciences Roundup: Blend, Amicus, Vertex, & More 12/21/12 Boston
Amicus-GlaxoSmithkline Drug for Fabry Disease Fails Clinical Trial 12/20/12 New York
Amicus Counts on “Chaperone” Tech to Enhance Rare Disease Treatments 01/11/12 New York
Shire Finds Big Value in Rare Diseases, and a Strong Growth Path for its Boston Unit 05/12/11 New York
Edimer, Third Rock’s Bet on Rare Diseases, Aims to Begin First Human Tests 03/15/11 Boston
Report: Fabry Patients Sue Genzyme and Mt. Sinai Medical School 03/11/11 Boston
Xconomy Readers Set $20B Pricetag on Genzyme—Is That Too Rich for Sanofi-Aventis? 07/29/10 Boston
Genzyme in “Tough Spot” with Icahn Proxy Challenge—CEO Termeer Courting Key Shareholders 05/13/10 Boston
Genzyme Starts Fabrazyme Trial 10/15/08 Boston
Page 1 of 1